Experience

Disease States

Continuum Clinical has deep experience across the full therapeutic spectrum.

  • Blood disorders
  • Cardiovascular conditions
  • Digestive diseases
  • Endocrine, nutritional and metabolic diseases
  • Genitourinary system diseases
  • Immune system disorders and viral diseases
  • Infectious diseases
  • Inflammatory diseases
  • Musculoskeletal disorders
  • Neurological (CNS) disorders
  • Oncological disorders
  • Ophthalmologic diseases
  • Orthopedics
  • Respiratory diseases
  • Sexual disorders
  • Skin and connective tissue conditions
  • Special categories (pediatrics, geriatrics, orphan diseases)

Representative Projects

Patient Recruitment

The right strategies. Flawless execution. The expertise to maximize any campaign. Since 1993, our Patient Recruitment practice has helped the world's leading healthcare companies accelerate clinical trial enrollment.

  • Enrolled 9000 patients in 6 months - accelerating enrollment by over a year - in support of a cardiovascular outcomes trial for an obesity drug.
  • Generated 500,000 inquiries and enrolled 4,000 patients 20 months ahead of schedule for a Phase III trial for women with hypoactive sexual desire disorder.
  • Undertook extensive market research to fine-tune communications underlying a recruitment campaign in irritable bowel syndrome, increasing the number of prequalified leads by 20% and accelerating enrollment by 3 months.
  • Exceeded enrollment goals by 25% for a complex recruitment program in Type 2 diabetes, enrolling over 1,000 patients across 4 protocols in 6 months.
  • Accelerated enrollment by 3 months for an overactive bladder clinical trial, enrolling 1,260 patients in 9 months.
  • Employed a focused digital strategy to target MS patients, enrolling 376 patients in 11 months, ahead of schedule.
  • Developed and implemented a targeted public relations strategy to enhance credibility with parents of infants, resulting in the enrollment of 245 subjects at 40% of the cost of traditional media.

Late Stage Research

With pioneering experience, Continuum's Late Stage team ensures peri- and post-approval projects are scientifically sound, strategically relevant, and operationally efficient.

  • Supported analytical activities for a 2 million+ patient, 1,800-site patient registry in acute myocardial infarction.
  • Developed HEOR endpoint recommendations for an investigational product in development for patients with treatment-naïve chronic lymphocytic leukemia.
  • Designed and implemented a 75,000-patient, 7,500-site, multinational observational study exploring compliance in the management of hypertension.
  • Developed a budget impact model to assess the clinical and financial impact of short- and long-acting opioids for acute and chronic pain management.
  • Designed and implemented a 5,000-patient, 400-site program of four separate orphan indication safety registries (lysosomal storage disorders), conducted in over 30 countries.
  • Designed and developed a risk prediction model to identify diabetes patients at risk for incurring high healthcare costs.
  • Designed and implemented a 2,500-patient, 200-site observational study in advanced melanoma examining safety and health economic outcomes, conducted in 19 countries.
  • Conducted a systematic literature review to identify the costs associated with hemodialysis in more than 25 countries.
  • Designed and implemented a 2,500-patient, 300-site pan-European registry, focused on patients with rheumatoid arthritis.
  • Developed a strategic pharmacoeconomic tactical plan to support the value proposition for a product used to reduce the risk of healthcare-associated infections.
  • Designed and implemented a 2,000-patient, 100-site registry in the management of schizophrenia.
  • Developed a global value dossier for a treatment used as first-line therapy for the management of patients with early multiple sclerosis.

In addition, our team recognizes the benefit that peer-reviewed publication affords our clients. Included on our extensive publication list (generally limited to the past ten years only) are the following:

  • Liu FX, Quock T, Burkhart J, Noe LL, Inglese G. Economic evaluations of peritoneal dialysis and hemodialysis: 2004-2012. F1000Research 2013;2:273 (doi: 10.12688/f1000research.2-273.v1).
  • Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH. Budget impact analysis of tapentadol extended-release (ER) for the treatment of moderate to severe chronic pain. Clin Ther 2013;35:659-72.
  • Weishaar, RE. Factors That Influence Patient Compliance for Observational Studies. Journal of Patient Compliance, Fall 2011
  • Weishaar, RE. Efficient and Cost-Effective Monitoring for Observational Studies, Journal of Clinical Studies, January 2011
  • Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R. Impact of solifenacin on quality of life, medical care use, work productivity and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatric Pharmacother 2009;7:373-382.
  • Noe L, Neil N, Ogden K, Turini M. Medical foods and foods for special medical purposes. Value Health 2009;12(7):A255 (Abstract).
  • Spalding J, Exuzides A, Colby C, Neil N, Noe L. Management of primary atrial fibrillation (AF): patient characteristics and hospital care setting. Value Health 2009;12(3):A153 (Abstract).
  • Trotter JP, Avoiding the Gas-Guzzler: Eight Steps to More Productive Observational Studies, HealthEconomics.com Newsletter, April 2009
  • Spalding J, Exuzides A, Colby C, Neil N, Noe L. Inpatient resource use among patients treated for primary atrial fibrillation (AF): role of clinical factors and choice of initial conversion therapy. Value Health 2009;12(3):A153 (Abstract).
  • Spalding J, Neil N, Exuzides A, Colby C, Noe L. Management of primary atrial fibrillation (AF): patient characteristics and hospital care setting. Abstract presented at the 10th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Apr 23-25, 2009, Washington, DC.
  • Spalding J, Exuzides A, Colby C, Neil N, Noe L. Inpatient resource use among patients treated for primary atrial fibrillation (AF): role of clinical factors and choice of initial conversion therapy. Abstract presented at the 10th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Apr 23-25, 2009, Washington, DC.
  • Spalding JR, Exuzides A, Adams S, Colby C, Noe L. Inpatient resource use associated with the treatment of secondary atrial fibrillation. Value Health 2008;11(6):A399 (Abstract).
  • Weishaar, RE. Shades of Gray: Segmenting the elderly population. Good Clin Pract Jan, 2008
  • Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K, Claus R, Andrews WT, Roach J. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clin Ther 2008;30:Theme Issue.
  • Belz M, Spalding J, Exuzides A, Adams S, Colby C, Noe L, Neil N. Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy. Value Health 2008;11(3):A200 (Abstract).
  • Belz M, Spalding J, Exuzides A, Adams S, Colby C, Neil N, Noe L. Likelihood of Adverse Events by Initial Acute Conversion Therapy Received Among Atrial Fibrillation Patients. Presented at the AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference, April 30 – May 2, 2008, Baltimore, MD.
  • Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008;24:1583-91.
  • Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008;23:2365-73.
  • Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro F. Economic evaluations of dialysis treatment modalities. Health Policy 2008;86:163-180.
  • Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro FT. Global economic evaluations of dialysis treatment modalities. Value Health 2007;10(6):A317 (Abstract).
  • Hansen R, Seifeldin R, Noe L. Medication adherence in post-transplant immunosuppression: the economic impact of drug-regimen complexity. Value Health. 2007;10(6):A368 (Abstract).
  • Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: Issues in posttransplant immunosupprestion. Transplant Proc 2007;Jun;39(5):1287-300.
  • Pasta D, Silva S, Noe LL, Claus R, Schaefer K, Andrews W, Roach J. Quality-adjusted length of stay analysis of hospitalized patients with asthma or COPD treated with Levalbuterol or Rcemic Albuterol. Value Health 2007;10(3):A110.
  • Claus R, Noe LL, Pasta D, Schaefer K, Andrews W, Roach J. Pharmacoeconomic outcomes of levalbuterol and racemic albuterol in hospitalized patients requiring nebulization therapy (POLARIS). Value Health 2007;10(3):A110.
  • Noe LL, Marshall TS, Rasouliyan L, Runken MC, Zinner NR. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly. Value Health 2007;10(3):A108.
  • Neil N, Block S, Ogden K, Noe LL, Black L, Williamson TE. Modeling the costs and outcomes of solifenacin vs. behavioral therapy or no therapy for treatment of overactive bladder in primary care. Pharmacotherapy 2005;25(10):1490.
  • Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Application of an algorithm for defining retrospective cohorts of colorectal cancer (CRC) patients treated with different first-line chemotherapy regiments +/- bevacizumab to administrative claims data. Value Health. 2005;8(6):A45.
  • Noe LL, Larson LR, Trotter JP, Utilizing Patient Registries to Support Health Economics Research: Integrating Observational Data with Economic Analyses, Models, and Other Applications, ISPOR Connections, October 2005
  • Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Development of an algorithm for the identification and classification of colorectal cancer (CRC) patients according to first-line chemotherapy regiments +/- bevacizumab, and initiation of second-line therapy using administrative claims. Value Health. 2005;8(6):A45.
  • Neil N, Lamm D, Ogden K, Noe LL, Peterson L, Mallick R. A simulation model of the cost of treatment failure in patients hospitalized with community-acquired pneumonia (CAP) in the US. Clin Microbiol Infect. 2005;11(Suppl 2):O59.
  • Noe LL, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Managed Care Interface. 2004 Nov;54-60.
  • Cranmer K, Gentry L, Weishaar RE. Into a Grey Area: Clinical Trials in the Elderly. Good Clin Pract J, 2004; 11; 28
  • Becker RV, Burke TA, McCoy MA, Trotter JP, A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare choice population, ClinTher, 2003: 24, 2: 647-662
  • Trotter JP. Patient registries: A new gold standard for "real world" research. The Ochsner Journal. 2002;4(4):211-4.
  • Sullivan DH, Morley JE, Johnson LE, Barber A, Olson JS, Stevens MR, Yamashita BD, Reinhart SP, Trotter JP, Olave XE. The GAIN (Geriatric Anorexia Nutrition) Registry: The impact of appetite and weight on mortality in a long-term care population. J Nutr Health Aging. 2002; 6(4):275-81.
  • Becker RV, Burke T, Williamson T, Trotter JP. An economic evaluation of the cost of edema and systolic blood pressure destabilization in cox-2-treated patients with osteoarthritis and hypertension. Value Health. 2001 Nov-Dec;4(6):485.
  • Lichtenstein GR, Keenan G, Chen DM, Shakur UM, Trotter JP. Crohn's disease severity and treatment: Impact on IBDQ scores. Am J Gastroenterol. 2001 Sep;96(9 Suppl):S298.
  • Healey M, Deverka P, Fox S, Gondek K, Edelman-Lewis B, Lydick E, Singh G, Temple R, Trotter JP, Methodological Issues in Pharmacoeconomic Evaluations — Clinical Studies, Value in Health, November, 2000
  • Lichtenstein GR, Keenan G, Vreeland MG, Chen DM. Infliximab tolerability in Crohn's disease patients. Am J Gastroenterol. 2001 Sep; 96(9 Suppl): S298.
  • Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR, Salzberg B, Hyams J, Schaible T, Vreeland MG, Larson LR, Trotter JP, Mummert LH, and Chen DM. TREAT registry results: Correlations between physician assessments of disease severity and IBDQ in Crohn's disease patients. Proceedings of the American College of Gastroenterology (ACG) Annual Conference; 2000 Oct; New York, New York.
  • Sandborn WJ, Lichtenstein GR, Feagan BG, Hanauer SB, Hyams J, Salzberg B, Schaible T, Vreeland MG, Larson LR, Mummert LH, Trotter JP. Long-term impact of Crohn's disease pharmacotherapy: TREAT registry baseline results. Presented at Capri 2000: International Meeting on Inflammatory Bowel Diseases; 2000 Jun;Capri, Italy.
  • Feagan BG, Vreeland MG, LarsonLR, et al. Annual cost of care for Crohn's disease: A payor perspective. Am J Gastroenterol. 2000;95(8):1955-60.
  • Feagan BG, Larson LR, VreelandMG, Bala MV. Annual cost of care for Crohn's disease patients. Proceedings of the American Gastroenterological Association (AGA) Annual Scientific Meeting; 1999 May; Orlando, Florida.
  • Trotter, J.P.: Health Economic Considerations in HIV Treatment. In Advances in the Management of Human Immunodeficiency Virus Infection: Implications for Managed Care. Supplement to Manage Care Interface, March, 1999.
  • Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heartfailure. Clin Ther. 1999;21(5):854-66.
  • Noe LL, Vreeland MG, Gore MG, Trotter JP. Initial, maintenance, and terminal care costs of breast cancer treatment. Value Health 1999;2(3):195.
  • Pleil AM, Calais M, Vreeland MG, Reinhart SP, Mummert LH, and Trotter JP. An economic assessment of dalteparin versus warfarin in total hip replacement. Value Health. 1999 Sep-Oct;2(5):350-1.
  • Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab. Clin Ther. 1998;20(5):1009-28.
List more publications

Medical Communications

Real-world evidence of product value and safety can only lead to improved patient outcomes when it is communicated with a deep understanding of targeted physicians, payers, policy-makers, patients, and other key stakeholders. And that requires planning!

  • Generated and analyzed insights from current clinical practice and patient experience to inform post-approval study design, supporting the introduction of a new therapy with a distinct mode of action and administration.
  • Combined clinical trial and real-world evidence to create targeted messages and tools that address clinical and payer barriers for the use of a branded medication in a highly generic market.
  • Created therapy-specific disease management resources for patients and healthcare professionals based on insights and experience generated through a product registry in multiple sclerosis.
  • Developed and tested value messages based on the Target Product Profile across multiple markets and identified evidence gaps to inform the late-stage clinical development plan.
  • Developed a white paper to establish disease burden and the clinical, social, emotional, quality-of-life, and financial impact associated with psoriasis.
Back to Top